| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.0013 | 1 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.0013 | 1 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.0012 | 1 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.00097 | 1 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.00092 | 1 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.00088 | 1 |